trial

A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder

NCTId NCT02161718
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 300 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2017-01-11
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
300 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-05
Primary completion
2017-01-11
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Olanzapine

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
David McDonnell, MDStudy Director

Sites

71 total
Little Rock, United StatesSpringdale, United StatesAnaheim, United StatesCulver City, United StatesGarden Grove, United StatesIrvine, United StatesLa Jolla, United StatesLong Beach, United StatesNational City, United StatesOakland, United StatesOceanside, United StatesOrange, United States

Linked catalysts

1
A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder — primary completion2017-01-11

Facts & assertions

4 sourced
Enrollment
300
Phase
PHASE2
Primary Completion Date
2017-01-11
Status
COMPLETED
relationships
The graph out of here
drug
Olanzapine
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
Alcoholism
indication
investigator
David McDonnell, MD
person